The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Frankly, these guys at LGB have been waffling on about Scancell for many years. They probably got a Grad to phone up a large list of companies for updates and they had little idea of what the Scancell rep (whoever that actually was) was telling them and scribbled out of context bobbins.
Fake news imo. Company RNS are what matters.
Sorry TF but that’s not right. There is suggestion of funding and as I rightly say, there is no evidence of that. Scancell are not present in the list of companies who have received funding. Ask yourself why not.
JB1 - you make some interesting connections and I always enjoy reading your well thought out posts. You could be right but there is currently no evidence of NextGen funding for SCOV, whilst there is very transparent evidence for other vaccines / companies. Surely if SCOV was in the mix, it would be amongst those on the list receiving the cash? Why would it not be?
Interesting article. Speculative of course but we have a ticket in the raffle……..
https://www.thisismoney.co.uk/money/comment/article-12904577/ALEX-BRUMMER-Big-pharma-bets-biotech-global-drugs-industry-booms.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html&_ga=2.186992808.1628934372.1703751373-1216378196.1703751373&_gl=1*111li14*_ga*MTIxNjM3ODE5Ni4xNzAzNzUxMzcz*_ga_XE0XLFFF16*MTcwMzc1MTM3My4xLjEuMTcwMzc1MTc5Ny4wLjAuMA..
You make a good point TF.
Perhaps it’s also worth condemning what each individual here would have done differently, if that news had come at a different time. Nothing in most cases I expect!
Thanks for your thoughts as always Burble.
As I understand it, iSCIB1 is also able to be used by a broader patient population and therefore also a catalyst for faster recruitment.
Data from that cohort is expected in H1 2024 according to past RNS and so given the limiting factors you describe, that approval cannot. I could be very wide of the mark an£ really hope I am but can’t help wondering if Scancell underestimated MHRA requirements due to the current trial progress and are now scrambling to supply what is needed. Each day that approval doesn’t arrive, is a day closer to the end of H1 2024.
Not intended to be a negative post as am very much pro-Scancell and the size of my investment backs that up but a concern all the same.
To save you the trouble Dartron, here’s what IC have to say about M&A activity:
“The three businesses acquired since the beginning of the financial year are trading in line with expectations and have increased the breadth of the group’s service offering while strengthening its existing regional presence. M&A aside, the group recorded a creditable 9 per cent organic revenue growth rate, achieved despite a quieter market for its advisory teams.
Management anticipates further growth in insolvency activity and a broadly consistent second half for financial advisory. Property advisory and transactional service volumes also provide cause for encouragement. The expanded “breadth” is also significant from an investment angle in that it acts as a bulwark against potential overexposure to any one business area.”
Clearly not a distraction in their view and in fact the exact opposite.
Bob on Dartron.
The positive and neutral IC article was actually published yesterday and I saw it without it being hidden behind a paywall. They don’t appear to believe acquisitions are a distraction either, or they would surely have mentioned it.
https://www.investorschronicle.co.uk/news/2023/12/11/begbies-traynor-finally-benefits-from-the-insolvency-lag/